Regeneron Pharmaceuticals (REGN) vs Vertex Pharmaceuticals (VRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed Vertex Pharmaceuticals (VRTX) over the past year, gaining 27.2% versus a gain of 23.2%. Over five years, VRTX leads with a +178.2% price change compared with +34.1% for REGN. Vertex Pharmaceuticals is the larger company by market cap ($127.59 billion vs $75.15 billion), about 1.7 times the size.
On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (11.9x vs 25.0x for Vertex Pharmaceuticals). Regeneron Pharmaceuticals pays a dividend yielding 0.50%, while Vertex Pharmaceuticals does not currently pay one. Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 31.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | REGN | VRTX |
|---|---|---|
| Share price | $729.95 | $503.40 |
| Market cap | $75.15B | $127.59B |
| 1-day change | -1.64% | -0.44% |
| YTD return | -3.85% | +11.53% |
| 1-year return | +27.24% | +23.24% |
| 5-year return | +34.14% | +178.18% |
| P/E ratio (TTM) | 18.05 | 29.32 |
| Forward P/E | 11.87 | 25.02 |
| EPS (TTM) | $40.44 | $17.17 |
| Dividend yield | 0.50% | 0.00% |
| Annual dividend | $3.64 | $0.00 |
| Revenue (latest FY) | $14.34B | $12.00B |
| Revenue growth (YoY) | +0.99% | +8.90% |
| Net income (latest FY) | $4.50B | $3.95B |
| Gross margin | — | 86.24% |
| Operating margin | 24.95% | 34.77% |
| Net margin | 31.41% | 32.94% |
| 52-week high | $859.34 | $560.25 |
| 52-week low | $541.00 | $402.58 |
| Distance from 52-week high | -15.06% | -10.15% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +17.30% | +13.51% |
| Average volume | 739.67K | 1.16M |
| Shares outstanding | 101.14M | 253.46M |
| Employees | 15,410 | 6,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vertex Pharmaceuticals trades at a higher earnings multiple (29.3x vs 18.1x trailing P/E).
- Vertex Pharmaceuticals grew revenue faster in its latest fiscal year (+8.90% vs +0.99%).
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
About Vertex Pharmaceuticals
VRTX stock →Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees
REGN vs VRTX FAQ
Which is bigger, Regeneron Pharmaceuticals or Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) is larger, with a market capitalization of $127.59B compared with $75.15B for Regeneron Pharmaceuticals (REGN).
Which stock has performed better over the past year, REGN or VRTX?
REGN returned +27.24% over the past 12 months, compared with +23.24% for VRTX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, REGN or VRTX?
REGN has the lower trailing P/E at 18.1, versus 29.3 for VRTX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Regeneron Pharmaceuticals or Vertex Pharmaceuticals?
Regeneron Pharmaceuticals pays a dividend yielding 0.50%, while Vertex Pharmaceuticals does not currently pay a regular dividend.
Are Regeneron Pharmaceuticals and Vertex Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.